Four years after near-death experience, PhIII data bring good news for Novavax

Novavax is celebrating trial results again four years after a Phase III failure in RSV sent their stock price off a cliff.

The company announced that their recombinant flu vaccine NanoFlu met all primary and secondary endpoints in a Phase III study of 2,652 adults older than 65. The numbers, Novavax suggested, should allow them to clear regulatory hurdles and snag the biotech’s first approval since its founding in 1987.